At Vaxcyte, we are driven by our:
Sense of Urgency
“Not since the 1950s has vaccine innovation been as relevant as today. Vaccines are now recognized for the true value they bring in protecting all of us from serious diseases.”
Jim Wassil, Executive Vice President and Chief Operating Officer
Eliminating Invasive Bacterial Infections
Despite renewed interest in vaccine innovation, bacterial infectious diseases have not historically received adequate attention. The global incidence of pneumococcal disease remains high, driven in part by emerging serotypes not covered by currently available vaccines. Our site-specific conjugation technology allows us to engineer broader-spectrum pneumococcal conjugate vaccines (PCVs) that we believe may enable our PCV franchise to surpass the coverage of other pneumococcal vaccines and provide greater disease protection, while maintaining effectiveness.
A Cause Befitting Our Technology
With our novel technology, we believe we can go beyond traditional vaccine approaches – such as new technologies like mRNA – when it comes to addressing bacterial diseases.
We are working to develop vaccines that improve upon those that are available or forge into new areas where prevention has not been possible. It’s more than incremental change. To me it’s a chance to markedly expand the role vaccines play in treating global health.